Risk of cancer in patients exposed to gabapentin in two electronic medical record systems

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 2, 2012, Pages 214-225

  Irizarry, Michael C ^a   Webb, David J ^b   Boudiaf, Nada ^b   Logie, John ^b   Habel, Laurel A ^c   Udaltsova, Natalia ^c   Friedman, Gary D ^c  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c DIVISION OF RESEARCH   (United States)

Author keywords

Cancer; Gabapentin; Protopathic bias

Indexed keywords

GABAPENTIN;

ANUS CANCER; ARTICLE; BLADDER CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INDUCED CANCER; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PENIS CANCER; PRIORITY JOURNAL; RECTUM CANCER; STOMACH CANCER; UNITED STATES;

AGED; AGED, 80 AND OVER; AMINES; ANTICONVULSANTS; CALIFORNIA; CASE-CONTROL STUDIES; COHORT STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; RISK; UNITED STATES;

EID: 84856253962     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2266     Document Type: Article

References (25)

1. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm 2003; 9(6): 559-568.
2. Raphael J, Ahmedzai S, Hester J, et al. Cancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med 2010; 11(5): 742-764.
3. Sigler RE, Gough AW, de la Iglesia FA. Pancreatic acinar cell neoplasia in male Wistar rats following 2years of gabapentin exposure. Toxicology 1995; 98(1-3): 73-82.
4. Friedman GD, Udaltsova N, Chan J, Quesenberry CP, Jr., Habel LA. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control 2009; 20: 1821-1835.
5. National Cancer Institute. SEER Program Coding and Staging Manual. National Cancer Institute: Bethesda, MD, 2007.
6. Habel LA, Friedman GD. Pharmaceuticals Other than Hormones. In Cancer Epidemiology and Prevention (2nd edn), Schottenfeld D, Fraumeni JF (eds.). Oxford Univ. Press: Oxford, 1996; pp. 489-506.
7. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. QJM 1998; 91(6): 445-452.
8. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6(12): 699-708.
9. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134(1): 95-101.
10. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92(11): 2076-2083.
11. Lipworth L, Tarone RE, Lund L, McLaughlin JK. Epidemiologic characteristics and risk factors for renal cell cancer. Clin Epidemiol 2009; 1: 33-43.
12. Kaye JA, Meier CR, Walker AM, Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer 2002; 86(9): 1436-1439.
13. Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the General Practice Research Database. Epidemiology 2001; 12(6): 690-694.
14. Lindblad M, Lagergren J, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2005; 14(2): 444-450.
15. Risk of cancer in patients exposed to gabapentin in the GPRD. GSK Clinical Trial Register. 2011.
16. Breslow NE, Day NE. Modelling the relationship between risk, dose and time. In Statistical Methods in Cancer Research Volume II: The Design and Analysis of Cohort Studies, Breslow NE, Day NE (eds.). International Agency for Research on Cancer: Lyon, France, 1987; pp. 232-271.
17. Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sorensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther 2002; 9(3): 199-205.
18. Tamim H, Monfared AA, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007; 16(3): 250-258.
19. Feinstein AR, Horwitz RI. An algebraic analysis of biases due to exclusion, susceptibility, and protopathic prescription in case-control research. J Chronic Dis 1981; 34(8): 393-403.
20. Horwitz RI, Feinstein AR. The problem of protopathic bias in case-control studies. Am J Med 1980; 68(2): 255-258.
21. Johnson AG, Jick SS, Perera DR, Jick H. Histamine-2 receptor antagonists and gastric cancer. Epidemiology 1996; 7(4): 434-436.
22. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363(9414): 1049-1057.
23. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69(1): 4-14.
24. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349(9051): 525-528.
25. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160(3): 349-353.